{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-028999","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2025-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.179809+00:00","generated_at":"2026-05-16T12:14:09.614556+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lixte expands ovarian cancer trial to 42 patients; expects initial data in H1 2026","bullets":["Amendment No.2 to collaborative study doubles enrollment from 21 to 42 patients for LB-100 + dostarlimab trial in ovarian clear cell carcinoma.","Lixte enters new Collaborative Research Agreement with MD Anderson; pays milestone payments up to $1.5M ($500k per event) plus 3.75% royalty on net profit.","GSK and Lixte provide drugs at no cost to institution for expanded 42-patient study; no additional GSK payments beyond original 21 subjects.","Initial data from first 21 patients expected in first half of 2026; trial led by MD Anderson includes Northwestern as second site."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-028999","json":"https://secwatch.observer/filing/0001493152-25-028999.json","markdown":"https://secwatch.observer/filing/0001493152-25-028999.md","text":"https://secwatch.observer/filing/0001493152-25-028999.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315225028999/0001493152-25-028999-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315225028999/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:14:09.614556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5128ca14667d7f751b4a5aa1b9d58d7638d81d75","claim":"LIXTE BIOTECHNOLOGY HOLDINGS, INC. entered into Collaborative Research Agreement with The University of Texas M.D. Anderson Cancer Center (effective 2025-12-17).","evidence_excerpt":"On December 17, the Company entered into a Collaborative Research Agreement with the Anderson Cancer Center (the “Research Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315225028999/0001493152-25-028999-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"The University of Texas M.D. Anderson Cancer Center"},{"label":"Effective","value":"2025-12-17"}],"fact_type":"material_agreement"},{"claim_id":"7e0fba94216bee32ae0d384bc2a8c8955f12382b","claim":"LIXTE BIOTECHNOLOGY HOLDINGS, INC. amended Amendment No.2 with GlaxoSmithKline LLC and The University of Texas M.D. Anderson Cancer Center (effective 2025-12-17).","evidence_excerpt":"On December 17, 2025, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), entered into Amendment No.2 (“Amendment No.2”) to the GSK & LIXTE Supported Collaborative Study (the “Collaborative Study”) by and between the Company, GlaxoSmithKline LLC (“GSK”) and the University of Texas M.D. Anderson Cancer Center","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315225028999/0001493152-25-028999-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"GlaxoSmithKline LLC and The University of Texas M.D. Anderson Cancer Center"},{"label":"Effective","value":"2025-12-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}